Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Alexion gets pexelizumab SPAs

(ALXN) and partner Procter & Gamble (PG) received Special Protocol Assessments (SPAs) from FDA for two international Phase

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE